JPH04364119A - Bathing agent composition - Google Patents

Bathing agent composition

Info

Publication number
JPH04364119A
JPH04364119A JP16521191A JP16521191A JPH04364119A JP H04364119 A JPH04364119 A JP H04364119A JP 16521191 A JP16521191 A JP 16521191A JP 16521191 A JP16521191 A JP 16521191A JP H04364119 A JPH04364119 A JP H04364119A
Authority
JP
Japan
Prior art keywords
sodium
weight
bath
agent composition
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP16521191A
Other languages
Japanese (ja)
Inventor
Yasuhiro Yoshida
吉田泰弘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsumura and Co
Original Assignee
Tsumura and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsumura and Co filed Critical Tsumura and Co
Priority to JP16521191A priority Critical patent/JPH04364119A/en
Publication of JPH04364119A publication Critical patent/JPH04364119A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To provide a bathing agent composition containing an alkaline inorganic salt and a proteinase, exhibiting slightly alkaline nature and excellent cleaning effect in dissolution, giving smoothing and refreshing feeling to the skin after bath and effective for the treatment of heat rashes, pimples, etc. CONSTITUTION:The objective bathing agent composition contains (A) an alkaline inorganic salt such as sodium carbonate, borax, sodium metasilicate and sodium sulfate (especially preferably sodium carbonate) and (B) a proteinase such as pancreatin obtained from the pancreas of pig or cattle (especially preferably a proteinase originated from microorganism of the genus Bacillus) and exhibits pH 8.0-10.0 when dissolved in bath water. The concentration of the alkaline inorganic salt such as sodium carbonate is adjusted to 20-200ppm, preferably 30-150ppm and the content of the proteinase is preferably selected to >=0.1wt.%.

Description

【発明の詳細な説明】[Detailed description of the invention]

【0001】0001

【産業上の利用分野】本発明は、優れた皮膚清浄化作用
を有し、入浴後の肌にすべすべ、さっぱりした爽快感を
もたらすとともに、あせも、にきび等の皮膚疾患に顕著
な改善効果を有する浴剤組成物に関する。
[Industrial Application Field] The present invention has an excellent skin cleansing effect, makes the skin smooth and refreshed after bathing, and has a remarkable improvement effect on skin diseases such as heat rash and acne. The present invention relates to bath agent compositions.

【0002】0002

【従来の技術】従来、浴湯に投入して用いられる浴剤組
成物としては種々のものが知られており、その組成は硫
酸ナトリウム、塩化ナトリウム、炭酸水素ナトリウム等
の無機塩類に香料、色素を加えたものが主である。これ
らの浴剤組成物は、血行促進、疲労回復、皮膚の清浄化
、心身のリラックス等の効果を目的とするものである。
[Prior Art] Various bath agent compositions have been known to be added to bath water, and their composition consists of inorganic salts such as sodium sulfate, sodium chloride, and sodium hydrogen carbonate, fragrances, and pigments. The main thing is the addition of . These bath agent compositions are intended to promote blood circulation, relieve fatigue, cleanse the skin, and relax the mind and body.

【0003】皮膚の汚れには、皮脂、垢、汗、埃があげ
られるが、入浴剤による皮膚の清浄化とは、主に炭酸水
素ナトリウムのアルカリ性によって皮脂を除去しようと
いうものである。
[0003] Skin stains include sebum, grime, sweat, and dust, and skin cleansing with bath additives primarily aims to remove sebum using the alkalinity of sodium bicarbonate.

【0004】しかしながら、炭酸水素ナトリウムのアル
カリ性は弱いため、一般的な浴剤組成物の使用濃度では
浴湯水のpHはほとんど変化せず中性付近であり、充分
な皮脂の除去効果が得られなかった。更に、皮脂除去効
果はわずかにあっても、角質の老廃物すなわち垢の除去
効果は全く認められなかった。
[0004] However, because the alkalinity of sodium hydrogen carbonate is weak, the pH of the bath water hardly changes at the concentration used in a typical bath agent composition and remains around neutral, making it impossible to obtain a sufficient sebum removal effect. Ta. Furthermore, although there was a slight sebum removal effect, no removal effect on dead skin cells, that is, scale, was observed.

【0005】そこで、垢の除去効果を高めるために、蛋
白質分解酵素を配合した浴剤組成物が開発された。
[0005] Therefore, in order to enhance the scale removal effect, a bath agent composition containing a proteolytic enzyme was developed.

【0006】ところが、一般的に浴剤組成物に使用され
る蛋白質分解酵素は、本来8.0から10.0のpH値
の条件下で最高の活性を示すものであるのに対し、従来
の浴剤組成物では、ほぼ中性の浴湯水で用いられている
ため所期の効果を発揮するはずがなく、結果として充分
な垢の除去効果が得られないのが現状である。
[0006] However, proteolytic enzymes generally used in bath agent compositions originally exhibit the highest activity under pH conditions of 8.0 to 10.0; Since bath agent compositions are used with almost neutral bath water, they cannot exhibit the desired effect, and as a result, the current situation is that a sufficient scale removal effect cannot be obtained.

【0007】更に、あせも・にきび等の皮膚疾患に対す
る顕著な症状改善効果を有する浴剤組成物は未だ開発さ
れていない。
[0007]Furthermore, a bath composition that has a remarkable symptom-improving effect on skin diseases such as heat rash and acne has not yet been developed.

【0008】[0008]

【解決しようとする課題】従って本発明は、優れた皮膚
清浄化作用を有し、入浴後の肌にすべすべ、さっぱりし
た爽快感をもたらすとともに、あせも、にきび等の皮膚
疾患に対して顕著な症状改善効果を有する浴剤組成物を
提供するものである。
[Problems to be Solved] Therefore, the present invention has an excellent skin cleansing effect, provides a smooth and refreshing feeling to the skin after bathing, and also provides noticeable symptoms for skin diseases such as heat rash and acne. The present invention provides a bath agent composition having improved effects.

【0009】[0009]

【課題を解決するための手段】本発明者等は、上述した
問題を解決すべく鋭意研究した結果、アルカリ性無機塩
類および蛋白質分解酵素を含有し、かつ溶解時に8.0
から10.0のpH値を示す浴剤組成物が優れた皮膚清
浄化作用を有し、入浴後の肌にすべすべ、さっぱりした
爽快感をもたらすとともに、あせも、にきび等の皮膚疾
患に対して顕著な症状改善効果を有することを見出し本
発明を完成した。
[Means for Solving the Problems] As a result of intensive research in order to solve the above-mentioned problems, the present inventors have developed a method that contains alkaline inorganic salts and proteolytic enzymes, and which has an 8.
A bath additive composition with a pH value of 10.0 to 10.0 has an excellent skin cleansing effect, leaving the skin smooth and refreshed after bathing, and is also effective against skin diseases such as heat rash and acne. The present invention was completed based on the discovery that it has a symptom-improving effect.

【0010】すなわち本発明は、アルカリ性無機塩類お
よび蛋白質分解酵素を含有し、かつ溶解時に8.0から
10.0のpH値を示すことを特徴とする浴剤組成物で
ある(以下、本発明の浴剤組成物という)。
[0010] That is, the present invention is a bath composition characterized by containing alkaline inorganic salts and proteolytic enzymes and exhibiting a pH value of 8.0 to 10.0 upon dissolution (hereinafter referred to as the present invention). bath agent composition).

【0011】以下、本発明の浴剤組成物の詳細を説明す
る。
The details of the bath agent composition of the present invention will be explained below.

【0012】本発明の浴剤組成物においてアルカリ性無
機塩類の具体例としては、炭酸ナトリウム、ホウ砂、メ
タケイ酸ナトリウム、硫化ナトリウム等があげられる。 中でも、安定性、安全性、アルカリ性の強さの点から炭
酸ナトリウムが好ましい。
Specific examples of alkaline inorganic salts in the bath agent composition of the present invention include sodium carbonate, borax, sodium metasilicate, and sodium sulfide. Among these, sodium carbonate is preferred in terms of stability, safety, and alkalinity.

【0013】水に溶かした時にアルカリ性を示す無機塩
類の配合量としては、浴湯が8.0から10.0のpH
値となる量が必要である。
[0013] The amount of inorganic salts that are alkaline when dissolved in water is such that the bath water has a pH of 8.0 to 10.0.
A quantity that is a value is required.

【0014】なぜなら、浴湯溶解時に8.0に満たない
pH値の場合には、アルカリ性による皮脂の除去効果が
発揮されないことに加えて、酵素活性も充分に発揮され
ず、結果的に発明の所期の目的が充分に達成されないか
らである。また、浴湯溶解時に10.0を越えるpH値
の場合は、アルカリ性が強すぎて皮膚に悪影響をおよぼ
し、好ましくない。炭酸ナトリウムを例にとると、浴湯
によって若干のバラツキはあるものの、浴湯中における
炭酸ナトリウムの濃度が20ppm以上200ppm以
下、好ましくは30ppm以上150ppm以下となる
ように調整することが必要である。
[0014] This is because, if the pH value is less than 8.0 when dissolved in bath water, the sebum removal effect due to alkalinity will not be exerted, and the enzyme activity will not be sufficiently exerted, resulting in the inventive problem. This is because the intended purpose is not fully achieved. Further, if the pH value exceeds 10.0 when dissolved in bath water, the alkalinity is too strong and it has an adverse effect on the skin, which is not preferable. Taking sodium carbonate as an example, although there is some variation depending on the bath water, it is necessary to adjust the concentration of sodium carbonate in the bath water to 20 ppm or more and 200 ppm or less, preferably 30 ppm or more and 150 ppm or less.

【0015】本発明の浴剤組成物における蛋白質分解酵
素は動物由来、微生物由来の蛋白質分解酵素を用いるこ
とがでる。
[0015] As the protease in the bath agent composition of the present invention, a protease derived from an animal or a microorganism can be used.

【0016】動物由来蛋白質分解酵素の具体例としては
、ブタ、ウシのすい臓より得られるパンクレアチンなど
が挙げられ、微生物由来蛋白質分解酵素の具体例として
は、バチルス(Bacillus)属の微生物より産生
されるビオプラーゼコンク(ナガセ生化学工業株式会社
)などがあげられるが、匂い、安定性、溶解性等の点か
ら、バチルス(Bacillus)属を起源とする微生
物由来の蛋白質分解酵素が好ましい。
[0016] Specific examples of animal-derived proteases include pancreatin obtained from the pancreas of pigs and cows, and specific examples of microbial-derived proteases include pancreatin produced by microorganisms of the genus Bacillus. Bioplase Conc (Nagase Seikagaku Kogyo Co., Ltd.) and the like are mentioned, but from the viewpoint of odor, stability, solubility, etc., proteolytic enzymes derived from microorganisms of the genus Bacillus are preferred.

【0017】蛋白質分解酵素の含有量としては、浴剤組
成物全体に対して0.1重量%以下では垢除去作用が十
分でないため、0.1重量%以上が望ましい。
The content of the proteolytic enzyme is desirably 0.1% by weight or more based on the entire bath agent composition, since if it is less than 0.1% by weight, the scale removal effect will not be sufficient.

【0018】更に本発明の浴剤組成物には、溶解時のp
Hおよび蛋白質分解酵素の安定性に影響を与えない限り
、以下に示す成分を添加することができる。
Furthermore, the bath agent composition of the present invention has a p
The following components can be added as long as they do not affect the stability of H and protease.

【0019】無機塩類 塩化ナトリウム、硝酸カリウム、硝酸ナトリウム、硝酸
カルシウム、硫酸アルミニウム、硫酸ナトリウム、ポリ
リン酸ナトリウム、塩化アンモニウム、硫酸鉄、リン酸
ナトリウム、硫酸マグネシウム、チオ硫酸ナトリウム、
炭酸水素ナトリウム、セスキ炭酸ナトリウム、硫化ナト
リウム、ホウ砂、酸化カルシウム、炭酸マグネシウム、
塩化カリウム、臭化カリウム、次亜硫酸ナトリウム等。
Inorganic salts sodium chloride, potassium nitrate, sodium nitrate, calcium nitrate, aluminum sulfate, sodium sulfate, sodium polyphosphate, ammonium chloride, iron sulfate, sodium phosphate, magnesium sulfate, sodium thiosulfate,
Sodium bicarbonate, sodium sesquicarbonate, sodium sulfide, borax, calcium oxide, magnesium carbonate,
Potassium chloride, potassium bromide, sodium hyposulfite, etc.

【0020】無機酸類 硼酸、メタケイ酸、無水ケイ酸等。[0020] Inorganic acids Boric acid, metasilicic acid, silicic anhydride, etc.

【0021】有機酸類 安息香酸、クエン酸、フマル酸、酒石酸、ピロリンドン
カルボン酸、サリチル酸、コハク酸、リンゴ酸等。
Organic acids such as benzoic acid, citric acid, fumaric acid, tartaric acid, pyrrolidonecarboxylic acid, salicylic acid, succinic acid, malic acid, etc.

【0022】生薬類 ソウジュツ、ビャクジュツ、カノコソウ、ケイガイ、コ
ウボク、センキュウ、トウキ、ショウキョウ末、ニンジ
ン、ケイヒ、シャクヤク、ハッカ葉、オウゴン、サンシ
シ、ブクリョウ、ドクカツ、ショウブ、ガイヨウ、マツ
ブサ、ビャクシ、ジュウヤク、サフラン、オウバクエキ
ス、チンピ、ウイキョウ、カン皮末、カミツレ、メリッ
サ、ローズマリー、マロニエ、アルニカ等。
[0022] Herbal medicines Sojutsu, Sandalwood, Valerian, Cucumber, Kobokou, Senkyu, Angelica, Ginger powder, Carrot, Keihi, Peony, Mentha leaf, Scutellariae, Sanshishi, Bukuriyo, Helicopter cutlet, Calamus, Samifolia, Alpinia, Juniperina, Juyaku, Saffron, oak extract, chimpi, fennel, can husk, chamomile, melissa, rosemary, horse chestnut, arnica, etc.

【0023】油脂類 ヌカ油、米ヌカエキス、テレビン油、イソプロピルパル
ミテート、イソプロピルミリステート、スクワラン、ト
リ(カプリル−カプリン酸)グリセリン、オリーブ油、
大豆油、流動パラフィン、ホホバ油、白色ワセリン等。
Fats and oils Bran oil, rice bran extract, turpentine oil, isopropyl palmitate, isopropyl myristate, squalane, tri(caprylic-capric) glycerin, olive oil,
Soybean oil, liquid paraffin, jojoba oil, white petrolatum, etc.

【0024】色素類 赤色2号、黄色4号、緑色3号、青色1号、赤色213
号、橙色205号、緑色201号、青色201号、赤色
106号、黄色202号の1、緑色204号等の厚生省
令タール色素別表第1及び第2の色素、クロロフィル、
リボフラビン、アンナット、カンタキサンチン、クロシ
ン、コチニール、べにばな、アントラキノン等の食品添
加剤として認められる天然色素。
Pigments Red No. 2, Yellow No. 4, Green No. 3, Blue No. 1, Red 213
No. 1, orange No. 205, green No. 201, blue No. 201, red No. 106, yellow No. 202, green No. 204, etc. Pigments listed in the Ministry of Health and Welfare Ordinance Tar Pigment Appended Table 1 and 2, Chlorophyll,
Natural pigments recognized as food additives such as riboflavin, annatto, canthaxanthin, crocin, cochineal, safflower, and anthraquinone.

【0025】アルコール類 エタノール、ステアリルアルコール、イソプロピルアル
コール、セチルアルコール、ヘキサデシルアルコール等
Alcohols ethanol, stearyl alcohol, isopropyl alcohol, cetyl alcohol, hexadecyl alcohol, etc.

【0026】多価アルコール類 グリセリン、プロピレングリコール、ソルビトール等。[0026] Polyhydric alcohols Glycerin, propylene glycol, sorbitol, etc.

【0027】界面活性剤類 ラウリン酸ナトリウム、ポリオキシエチレンラウリルエ
ーテル硫酸ナトリウム、ポリオキシエチレンアルキルエ
ーテル硫酸塩、ラウリン酸ジエタノールアミド、ポリエ
チレングリコールモノステアレート等。
Surfactants: sodium laurate, sodium polyoxyethylene lauryl ether sulfate, polyoxyethylene alkyl ether sulfate, lauric acid diethanolamide, polyethylene glycol monostearate, etc.

【0028】香料類 ラベンダー油、ジャスミン油、レモン油、ローズ油、オ
レンジ油、パイン油等の天然香料及びゲラニオール、シ
トロネロール、フェニルエチルアルコール、ベンジルア
セテート等の合成香料。
Fragrances Natural fragrances such as lavender oil, jasmine oil, lemon oil, rose oil, orange oil, pine oil, etc. and synthetic fragrances such as geraniol, citronellol, phenylethyl alcohol, benzyl acetate.

【0029】その他 イオウ、鉱砂、湯の花、カゼイン、中性白土、サリチル
酸ナトリウム、カルボキシメチルセルロースナトリウム
、卵黄末、いり糖、雲母末、脱脂粉乳、ポリビニルピロ
リドン等。
Other ingredients include sulfur, mineral sand, hot water, casein, neutral clay, sodium salicylate, sodium carboxymethyl cellulose, egg yolk powder, sucrose, mica powder, skim milk powder, polyvinylpyrrolidone, and the like.

【0030】更に本発明の浴剤組成物は、上記のもの以
外にも、必要に応じて殺菌防腐剤(例えば安息香酸、安
息香酸エステル、ソルビン酸等)、金属封鎖剤(例えば
EDTA、NTA、クエン酸等)アミノ酸、ビタミンな
ど、その他の広い範囲の原料を配合することができる。
Furthermore, in addition to the above, the bath agent composition of the present invention may optionally contain sterilizing preservatives (eg, benzoic acid, benzoic acid esters, sorbic acid, etc.), sequestering agents (eg, EDTA, NTA, A wide range of other raw materials such as citric acid, amino acids, and vitamins can be added.

【0031】混合機としては、粉体を撹拌、混合するた
めに使用されるものであればどのようなものでも使用で
きる。具体的にはバートオーミキサー、ナウターミキサ
ー、万能撹拌混合機、V字型混合機等をあげることがで
きる。また、浴剤組成物の混合時間は、構成成分が均一
に混合するのに必要な時間であればよく、上記の例にあ
げた混合機を使用する場合は通常、室温で5〜50分間
混合すればよい。
As the mixer, any device can be used as long as it is used for stirring and mixing powders. Specifically, examples thereof include a Bartoh mixer, a Nauta mixer, a universal stirring mixer, a V-shaped mixer, and the like. In addition, the mixing time for the bath agent composition may be as long as it is necessary for the constituent components to be mixed uniformly, and when using the mixer mentioned in the example above, the mixing time is usually 5 to 50 minutes at room temperature. do it.

【0032】つぎに、本発明の浴剤組成物と従来の浴剤
組成物とを比較した実験例をあげ、本発明の浴剤組成物
が優れた皮膚清浄化作用を有し、入浴後の肌のすべすべ
、さっぱりした爽快感をもたらすとともに、あせも、に
きび等の皮膚疾患に対して顕著な症状改善効果のあるこ
とを説明する。
Next, an experimental example comparing the bath agent composition of the present invention and a conventional bath agent composition will be given. It will be explained that it not only makes the skin smooth and feels refreshed, but also has a remarkable symptom-improving effect on skin diseases such as heat rash and acne.

【0033】[0033]

【実験例】[Experiment example]

■浴湯 第1表に示されるような組成を持つ、実施例1から5、
比較例1から5なる浴剤組成物を調整し、各浴剤組成物
を30g/200lの濃度(150ppm)となるよう
に、42°Cの浴湯に溶解して用いた。
■Bath water Examples 1 to 5 having the composition shown in Table 1,
Comparative Examples 1 to 5 bath agent compositions were prepared, and each bath agent composition was dissolved in 42° C. bath water to a concentration of 30 g/200 liters (150 ppm).

【0034】比較例は、市販の浴剤を参考に、蛋白質分
解酵素の含有するもの(比較例1)、蛋白質分解酵素の
含まないもの(比較例2から5)に分類して、用いた。
Comparative examples were classified into those containing proteolytic enzymes (Comparative Example 1) and those containing no proteolytic enzymes (Comparative Examples 2 to 5) with reference to commercially available bath additives.

【0035】第1表Table 1

【0036】■皮脂除去作用・垢除去作用・入浴感触健
康な男女10名に5分間入浴してもらい、入浴後に皮脂
除去作用、垢除去作用、入浴感触を評価した。その結果
を第2表に示す。なお、これらの試験法および評価基準
は以下によった。
■Sebum removal effect, scale removal effect, and bathing sensation Ten healthy men and women were asked to take a bath for 5 minutes, and after bathing, the sebum removal effect, scale removal effect, and bathing sensation were evaluated. The results are shown in Table 2. Note that these test methods and evaluation criteria were as follows.

【0037】(皮脂除去作用)入浴者の前腕部の5cm
×5cmの部分に牛脂0.1gを均一に塗り、入浴後に
残った牛脂をアセトンで抽出、留去し、重量を測定して
、抽出率(%)を求め、10名の平均値を算出し、下記
の基準にて評価した。
(Sebum removal effect) 5cm of the bather's forearm
Apply 0.1 g of beef tallow evenly on a 5 cm area, extract the remaining beef tallow after bathing with acetone, distill it off, measure the weight, determine the extraction rate (%), and calculate the average value of 10 people. , evaluated based on the following criteria.

【0038】(基準) ◎:油除去率80%以上 ○:油除去率50%以上80%未満 △:油除去率20%以上50%未満 ×:油除去率20%未満(Standard) ◎: Oil removal rate 80% or more ○: Oil removal rate 50% or more but less than 80% △: Oil removal rate 20% or more but less than 50% ×: Oil removal rate less than 20%

【0039】(垢除去作用)入浴後の浴場水をサンプリ
ングし、ローリー(Lowry)法により溶存タンパク
質の定量を行い、10名の平均値を算出し、下記の基準
にて評価した。
(Scale removal effect) Bath water after bathing was sampled, dissolved protein was quantified by the Lowry method, the average value of 10 people was calculated, and evaluation was made according to the following criteria.

【0040】(基準)比較例1の時の溶存タンパク質量
を100とした場合 ◎:溶存タンパク質量200以上 ○:溶存タンパク質量150以上200未満△:溶存タ
ンパク質量50以上150未満×:溶存タンパク質量5
0未満
(Standard) When the amount of dissolved protein in Comparative Example 1 is 100 ◎: Amount of dissolved protein 200 or more ○: Amount of dissolved protein 150 or more and less than 200 △: Amount of dissolved protein 50 or more and less than 150 ×: Amount of dissolved protein 5
Less than 0

【0041】(入浴感触)入浴後、入浴感触について下
記のように点数をつけてもらい、10名の平均値を算出
し、下記の基準にて評価した。
(Bath Feeling) After taking a bath, the participants were asked to score the feeling of bathing as shown below, and the average value of the 10 participants was calculated and evaluated based on the following criteria.

【0042】(点数) 2点:肌がたいへんすべすべ、さっぱりする。 1点:肌がややすべすべ、さっぱりする。 0点:肌が全くすべすべ、さっぱりしない。(Score) 2 points: Skin feels very smooth and refreshed. 1 point: Skin feels slightly smoother and refreshed. 0 points: Skin is not smooth or refreshed at all.

【0043】(基準) ◎:1.5点以上 ○:1.0点以上1.5点未満 △:0.5点以上1.5点未満 ×:0.5点未満(Standard) ◎: 1.5 points or more ○: 1.0 points or more but less than 1.5 points △: 0.5 points or more but less than 1.5 points ×: Less than 0.5 points

【0044】■あせもに対する効果 あせもの症状のある男女各々4名ずつに、1日1回5分
間、10日間繰り返して入浴してもらい、あせもに対す
る作用について下記のように点数をつけてもらい、4名
の合計点を算出し、下記の基準にて評価した。その結果
を第3表に示す。
[0044] Effect on heat rash Four men and women each with symptoms of heat rash were asked to take a bath repeatedly for 5 minutes once a day for 10 days, and were asked to rate the effect on heat rash as shown below. The total score was calculated and evaluated using the following criteria. The results are shown in Table 3.

【0045】(点数) 2点:著しい症状改善効果が認められる。 1点:若干の症状改善効果が認められる。 0点:全く効果は認められない。(Score) 2 points: Significant symptom improvement effect is observed. 1 point: Some symptom improvement effect is observed. 0 points: No effect observed at all.

【0046】(基準) 4点以上:○ 2〜3点:△ 0〜1点:×(Standard) 4 points or more:○ 2-3 points: △ 0-1 points: ×

【0047】■にきびに対する効果 浴湯にガーゼを浸し、にきびの症状のある男女4名ずつ
に、1日1回10分間、患部をこのガーゼで浸し、その
後に水で洗顔する操作を10日間繰り返した。そしてに
きびに対する作用について下記のように点数をつけても
らい、4名の合計点を算出し、下記の基準にて評価した
。その結果を第4表に示す。
■ Effect on acne Soak gauze in bath water and have 4 men and women with acne symptoms soak their affected areas in this gauze for 10 minutes once a day, then wash their faces with water for 10 days. Ta. The participants were asked to score the effect on acne as shown below, and the total score of the four participants was calculated and evaluated based on the following criteria. The results are shown in Table 4.

【0048】(点数) 2点:著しい症状改善効果が認められる。 1点:若干の症状改善効果が認められる。 0点:全く効果認められない。(Score) 2 points: Significant symptom improvement effect is observed. 1 point: Some symptom improvement effect is observed. 0 points: No effect observed at all.

【0049】(基準) 4点以上:○ 2〜3点:△ 0〜1点:×(Standard) 4 points or more:○ 2-3 points: △ 0-1 points: ×

【0050】第2表Table 2

【0051】第3表Table 3

【0052】第4表Table 4

【0053】[発明の効果]第2表、第3表、第4表に
示されるとおり、本発明の浴剤組成物が優れた皮膚清浄
化作用を有し、入浴後の肌にすべすべ・さっぱりとした
爽快感をもたらすとともに、あせも・にきび等の皮膚疾
患に対して、顕著な症状改善効果をもつことがわかる。
[Effects of the Invention] As shown in Tables 2, 3, and 4, the bath agent composition of the present invention has an excellent skin cleansing effect, leaving the skin smooth and refreshed after bathing. In addition to providing a refreshing feeling, it has been shown to have a significant symptom-improving effect on skin diseases such as heat rash and acne.

【0054】本発明の浴剤組成物が上記のような効果を
もつ理由は、浴湯水をpH8.0以上のアルカリ性とす
ることによって、十分な皮脂汚れの除去効果が得られる
と同時に、浴湯水がアルカリ性となることによって酵素
の活性が飛躍的に増大し、それに伴って垢の除去効果も
格段に増強され、それら二つの効果が相乗的に働いて、
優れた効果を発現している。
The reason why the bath agent composition of the present invention has the above-mentioned effects is that by making the bath water alkaline with a pH of 8.0 or more, a sufficient effect of removing sebum stains can be obtained, and at the same time, the bath water By becoming alkaline, enzyme activity increases dramatically, and the scale removal effect is also greatly enhanced, and these two effects work synergistically,
It has shown excellent effects.

【0055】以下に、本発明の浴剤組成物の実施例を示
して、本発明をさらに詳細に説明するが、本発明はこれ
により何等制限されるものではない。
[0055] The present invention will be explained in more detail below by showing examples of the bath agent composition of the present invention, but the present invention is not limited thereto.

【0056】実施例1 炭酸ナトリウム            20.0重量
部硫酸ナトリウム            50.0重
量部塩化ナトリウム            28.0
重量部パンクレアチン            2.0
重量部
Example 1 Sodium carbonate 20.0 parts by weight Sodium sulfate 50.0 parts by weight Sodium chloride 28.0 parts by weight
Part by weight pancreatin 2.0
Weight part

【0057】実施例2 炭酸ナトリウム            50.0重量
部硫酸ナトリウム            20.0重
量部塩化ナトリウム            28.0
重量部パンクレアチン            2.0
重量部
Example 2 Sodium carbonate 50.0 parts by weight Sodium sulfate 20.0 parts by weight Sodium chloride 28.0 parts by weight
Part by weight pancreatin 2.0
Weight part

【0058】実施例3 炭酸ナトリウム            20.0重量
部硫酸ナトリウム            50.0重
量部塩化ナトリウム            29.5
重量部ビオプラーゼコンク        0.5重量
Example 3 Sodium carbonate 20.0 parts by weight Sodium sulfate 50.0 parts by weight Sodium chloride 29.5
Part by weight Bioplase Conc 0.5 part by weight

【0059】実施例4 炭酸ナトリウム            50.0重量
部塩化ナトリウム            49.9重
量部ビオプラーゼコンク        0.1重量部
Example 4 Sodium carbonate 50.0 parts by weight Sodium chloride 49.9 parts by weight Bioplase conc 0.1 part by weight

【0060】実施例5 硫化ナトリウム            50.0重量
部硫酸ナトリウム            49.5重
量部ビオプラーゼコンク        0.5重量部
Example 5 Sodium sulfide 50.0 parts by weight Sodium sulfate 49.5 parts by weight Bioplase conc 0.5 parts by weight

【0061】実施例6 炭酸ナトリウム            42.0重量
部炭酸水素ナトリウム        27.0重量部
硫酸ナトリウム            28.2重量
部センキュウ  エキス        0.5重量部
パンクレアチン            1.8重量部
香料                      0
.3重量部黄色202号の(1)      0.2重
量部
Example 6 Sodium carbonate 42.0 parts by weight Sodium hydrogen carbonate 27.0 parts by weight Sodium sulfate 28.2 parts by weight Pancreaticum extract 0.5 parts by weight Pancreatin 1.8 parts by weight Flavor 0
.. 3 parts by weight Yellow No. 202 (1) 0.2 parts by weight

【0062】実施例7 炭酸ナトリウム            72.0重量
部塩化ナトリウム            24.5重
量部ビオプラーゼコンク        0.5重量部
ホホバ油                  0.5
重量部プロピレングリコール      1.5重量部
香料                      0
.5重量部青色1号                
  0.5重量部
Example 7 Sodium carbonate 72.0 parts Sodium chloride 24.5 parts Bioplase conc 0.5 parts Jojoba oil 0.5 parts by weight
Parts by weight Propylene glycol 1.5 parts by weight Fragrance 0
.. 5 parts by weight Blue No. 1
0.5 parts by weight

【0063】実施例8 炭酸ナトリウム            48.0重量
部硫酸マグネシウム          49.9重量
部炭酸カルシウム            1.0重量
部ピオプラーゼコンク        0.3重量部香
料                      0.
4重量部緑色204号              0
.4重量部
Example 8 Sodium carbonate 48.0 parts by weight Magnesium sulfate 49.9 parts by weight Calcium carbonate 1.0 parts by weight Pioprase conc. 0.3 parts by weight Fragrance 0.
4 parts by weight Green No. 204 0
.. 4 parts by weight

【0064】上記の実施例1から8の処方に
従って均一に混合した各浴剤組成物を30g/200l
の濃度(150ppm)となるように、42°Cの浴湯
に溶解して用いた。
30 g/200 liters of each bath agent composition uniformly mixed according to the formulations of Examples 1 to 8 above.
It was dissolved in bath water at 42°C to give a concentration of 150 ppm.

【0065】その結果、いずれも優れた皮膚清浄化作用
を有し、入浴後の肌にすべすべ、さっぱりとした爽快感
をもたらすとともに、あせも、にきび等の皮膚疾患に対
して顕著な症状改善効果を有することが認められた。
As a result, all of them have an excellent skin cleansing effect, leaving the skin smooth and refreshed after bathing, as well as having a remarkable symptom-improving effect on skin diseases such as heat rash and acne. It was recognized that the

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】アルカリ性無機塩類および蛋白質分解酵素
を含有し、かつ浴湯溶解時に8.0から10.0のpH
値を示すことを特徴とする浴剤組成物。
Claim 1: Contains alkaline inorganic salts and proteolytic enzymes, and has a pH of 8.0 to 10.0 when dissolved in bath water.
A bath agent composition characterized in that it exhibits a value.
JP16521191A 1991-06-11 1991-06-11 Bathing agent composition Pending JPH04364119A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP16521191A JPH04364119A (en) 1991-06-11 1991-06-11 Bathing agent composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16521191A JPH04364119A (en) 1991-06-11 1991-06-11 Bathing agent composition

Publications (1)

Publication Number Publication Date
JPH04364119A true JPH04364119A (en) 1992-12-16

Family

ID=15807960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16521191A Pending JPH04364119A (en) 1991-06-11 1991-06-11 Bathing agent composition

Country Status (1)

Country Link
JP (1) JPH04364119A (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048775A1 (en) * 1997-02-12 1998-11-05 Johnson & Johnson Consumer Companies, Inc. Serine protease and topical retinoid compositions
FR2817475A1 (en) * 2000-12-04 2002-06-07 Rocher Yves Biolog Vegetale Use of a composition, comprises proteases and a retinol source to combat skin aging
JP2009292809A (en) * 2008-05-09 2009-12-17 Kracie Home Products Ltd Skin touch feeling improver and skin cosmetic compounded with the same, and method for improving skin touch feeling
JP2012514602A (en) * 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー Compositions and methods for the treatment or prevention of S. aureus infections and compositions and methods for the eradication or reduction of S. aureus on the surface
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048775A1 (en) * 1997-02-12 1998-11-05 Johnson & Johnson Consumer Companies, Inc. Serine protease and topical retinoid compositions
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US9624525B2 (en) 1999-12-17 2017-04-18 Curemark, Llc Method for treating pervasive development disorders
US9624526B2 (en) 1999-12-17 2017-04-18 Curemark Llc Method for treating pervasive development disorders
US9233146B2 (en) 2000-08-14 2016-01-12 Curemark, Llc Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US10209253B2 (en) 2000-11-16 2019-02-19 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US9377459B2 (en) 2000-11-16 2016-06-28 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
FR2817475A1 (en) * 2000-12-04 2002-06-07 Rocher Yves Biolog Vegetale Use of a composition, comprises proteases and a retinol source to combat skin aging
US11033563B2 (en) 2005-08-30 2021-06-15 Curemark, Llc Use of lactulose in the treatment of autism
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US10350229B2 (en) 2005-08-30 2019-07-16 Curemark, Llc Use of lactulose in the treatment of autism
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9925250B2 (en) 2008-03-13 2018-03-27 Curemark, Llc Method of treating proteinuria in pregnancy
US9408895B2 (en) 2008-03-13 2016-08-09 Curemark, Llc Method of treating pregnancy-induced hypertension
US11045527B2 (en) 2008-03-13 2021-06-29 Curemark, Llc Method of diagnosing preeclampsia or pregnancy-induced hypertension
US10272141B2 (en) 2008-04-18 2019-04-30 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US11235038B2 (en) 2008-04-18 2022-02-01 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9687534B2 (en) 2008-04-18 2017-06-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
JP2009292809A (en) * 2008-05-09 2009-12-17 Kracie Home Products Ltd Skin touch feeling improver and skin cosmetic compounded with the same, and method for improving skin touch feeling
US10588948B2 (en) 2008-06-26 2020-03-17 Curemark, Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US9687535B2 (en) 2008-10-03 2017-06-27 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
US10413601B2 (en) 2008-10-03 2019-09-17 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
JP2012514602A (en) * 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー Compositions and methods for the treatment or prevention of S. aureus infections and compositions and methods for the eradication or reduction of S. aureus on the surface
US9895427B2 (en) 2009-01-06 2018-02-20 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US10736946B2 (en) 2009-01-06 2020-08-11 Galenagen, Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US11357835B2 (en) 2009-01-06 2022-06-14 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
JP2015129135A (en) * 2009-01-06 2015-07-16 キュレロン リミテッド ライアビリティ カンパニー Compositions and methods for treatment or prevention of staphylococcus aureus infections, and compositions and methods for eradication or reduction of staphylococcus aureus on surfaces
US9931302B2 (en) 2009-04-13 2018-04-03 Curemark , LLC Enzyme delivery systems and methods of preparation and use
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US11419821B2 (en) 2009-04-13 2022-08-23 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9415014B2 (en) 2009-04-13 2016-08-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US10098844B2 (en) 2009-04-13 2018-10-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US10716835B2 (en) 2009-10-21 2020-07-21 Curemark, Llc Methods and compositions for the prevention and treatment of influenza
US10940187B2 (en) 2011-04-21 2021-03-09 Curemark, Llc Method of treatment of schizophreniform disorder
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US10279016B2 (en) 2011-04-21 2019-05-07 Curemark, Llc Method of treatment of schizophreniform disorder
US9492515B2 (en) 2011-04-21 2016-11-15 Curemark, Llc Method of treatment of schizophreniform disorder
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11364287B2 (en) 2012-05-30 2022-06-21 Curemark, Llc Methods of treating celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Similar Documents

Publication Publication Date Title
JPH04364119A (en) Bathing agent composition
CN101454008A (en) Dental appliance cleanser
CN107603789B (en) Conditioning type solid shampoo soap
EP0529931A2 (en) Water modifier
US6210694B1 (en) Cosmetic composition containing charcoal and process for the preparation thereof
CN105342922A (en) Shower gel and preparation method thereof
JP2007051167A (en) Transparent gel-like detergent composition
JP2523311B2 (en) Bath agent
CN106214611A (en) A kind of face cleaning salt composite, its preparation method and the method that skin of face is carried out
JPH01186814A (en) Face-washing, shampooing and bathing agent
JP7430009B2 (en) Skin care cosmetics without sodium hydroxide and potassium hydroxide
JPH0334919A (en) Bathing agent
JPH09286718A (en) Bath article composition
JPH07309741A (en) Bathing agent composition
JP3568603B2 (en) Bath composition
JP3457395B2 (en) Bath composition
JPH03109497A (en) Detergent composition having low stimulating property
JP2006188435A (en) Skin-cleansing agent composition
JP2811736B2 (en) Bath composition
JPH07228524A (en) Bathing agent for jet bath
JP2002105488A (en) Detergent composition
RU2196567C1 (en) Detergent
JPH07228519A (en) Bathing agent for jet bath
CN115487094A (en) Sleep-aiding skin-care cleaning composition and preparation method thereof
CN112438927A (en) Sea salt mite-removing acne-removing clean and fragrant body wash and production method thereof